Imidazo[2,1-b]-1,3,4-thiadiazole, 2-methoxy-6-[6-methoxy-4-[(2-phenyl-4-thiazolyl)methoxy]-2-benzofuranyl]- manufacturers
- VU0652925
-
- $2980.00
-
2026-07-27
- CAS:1476847-58-1
- Purity:
- Supply Ability: 10g
|
| | Imidazo[2,1-b]-1,3,4-thiadiazole, 2-methoxy-6-[6-methoxy-4-[(2-phenyl-4-thiazolyl)methoxy]-2-benzofuranyl]- Basic information |
| | Imidazo[2,1-b]-1,3,4-thiadiazole, 2-methoxy-6-[6-methoxy-4-[(2-phenyl-4-thiazolyl)methoxy]-2-benzofuranyl]- Chemical Properties |
| density | 1.50±0.1 g/cm3(Predicted) | | pka | 0.55±0.10(Predicted) |
| | Imidazo[2,1-b]-1,3,4-thiadiazole, 2-methoxy-6-[6-methoxy-4-[(2-phenyl-4-thiazolyl)methoxy]-2-benzofuranyl]- Usage And Synthesis |
| Description | VU0652925 is a PAR4 antagonist. VU0652925 had a PAC1 IC50 of 43.0 pM (-pIC50±SEM: 10.4±0.04) and a P-sel IC50 of 39.2 pM (-pIC50±SEM: 10.41±0.04). PAR4 antagonists is potential useful for the development of tools such as radioligands and PET tracers that are not currently available to the field for this target. | | Uses | VU0652925, an analog of BMS986120, is a PAR4 antagonist, with IC50 values of 43 pM and 39.2 pM for PAC1 and P-selectin, respectively. VU0652925 is able to suppress GPIIbIIIa activation[1]. | | References | [1] Matthew T Duvernay, et al. Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets. Mol Pharmacol. 2017 Jan;91(1):39-47. DOI:10.1124/mol.116.106666 |
| | Imidazo[2,1-b]-1,3,4-thiadiazole, 2-methoxy-6-[6-methoxy-4-[(2-phenyl-4-thiazolyl)methoxy]-2-benzofuranyl]- Preparation Products And Raw materials |
|